Researchers from Uppsala University and Tomsk Polytechnic University have detailed the discovery and preclinical evaluation of [177Lu]BQ-7876, a novel prostate-specific membrane antigen (PSMA)-targeting therapeutic for the treatment of prostate cancer.
Raising capital has always been a challenge for small to medium biotech firms worldwide, but the economic whiplash and the wider downturn across international markets post-pandemic have pushed Chinese biotechs to make-it-or-break-it scenarios for crossing the IPO threshold, speakers at the Chinabio Partnering Forum 2023 said in Shanghai.
Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
“Why do the top 10 pharmaceutical companies remain in the top 10?” asked Li Chen, founder and CEO of Hua Medicine, to audience members at the Chinabio Partnering Forum in Shanghai on Sept. 20. “[It comes down to] their ability to innovate themselves, but also the capability to acquire technology from partnerships, [to] manufacture and sell in countries like the U.S."
The discovery of new 68Ga-labeled CD38-targeted peptides for PET imaging was recently discussed by researchers from Peking University First Hospital and China National Center For Nanoscience & Technology.
New and updated clinical data presented by biopharma firms at the International Association for the Study of Lung Cancer, 2023 World Conference on Lung Cancer, including: Astrazeneca, Daiichi.
Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, regeneration and homeostasis.
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
RSS
